Can You Get Mounjaro for Free on the NHS?

You've searched this because you don't want to pay, here's the real picture

Most people searching this question have already read something promising about Mounjaro's results and are hoping there is a straightforward route that doesn't involve a private prescription fee. That hope isn't unreasonable. Mounjaro is funded by the NHS (NICE recommended tirzepatide for weight management in December 2024, as confirmed in NICE technology appraisal TA1026) but the rollout is deliberately phased, and the entry criteria in the early phases are demanding by design.

The first cohort to qualify needed a BMI of 40 or above plus four or more of five specific conditions: high blood pressure, raised cholesterol, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. In June 2026, a second cohort opened, BMI 35–39.9 with the same four-condition requirement. Subsequent phases will broaden access further, reaching people with fewer qualifying conditions and lower BMIs, but the next scheduled expansion is not until around March 2027. If your BMI sits at 30 or your only weight-related condition is prediabetes, free NHS access is not on the table at the moment.

Worth knowing: even within a qualifying cohort, your GP's practice has to be participating. From April 2026, GP practices may prescribe Mounjaro under the new QOF contract, but this is optional, not every surgery has signed up, and availability varies between areas. Checking with your GP directly takes under a minute and is the fastest way to find out whether your practice is part of the programme.

What the NHS route actually involves once you qualify

NHS prescriptions for Mounjaro are not handed over at a single appointment. Patients must be enrolled in a structured weight-management programme that includes dietary guidance and support for increased physical activity. That wraparound care is a condition of treatment, not an optional add-on. For many patients this means joining a waiting list for a specialist service before the medicine is even discussed.

Semaglutide (Wegovy) follows a different NICE pathway (TA875) with its own eligibility thresholds and a requirement to use the medicine within a specialist weight management service for a maximum of two years. The NHS access picture for weight-loss medicines is therefore not one queue but several, each with its own criteria. Our page on getting Mounjaro through your GP covers what the GP-led prescription route looks like in practice, including what to take to that conversation.

If you do meet the NHS criteria and your practice is participating, a standard NHS prescription charge applies in England (or none in Wales, Scotland and Northern Ireland under their respective arrangements). Our page on getting Mounjaro for free explains the full range of routes people explore, including exemption certificates and NHS eligibility, and what realistically applies in each case. The medicine itself is not free of charge in the conventional sense, the NHS pays the cost, and in England you pay the standard prescription charge unless you hold an exemption certificate.

The private route: what it costs and what clinical assessment involves

For people who don't meet NHS thresholds or who cannot wait, private treatment through a regulated online pharmacy is the practical alternative. The licensed eligibility criteria for private prescribing broadly follow the medicine's UK authorisation: adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber still makes the final call, BMI alone doesn't guarantee a prescription.

Private pricing has shifted since Eli Lilly raised UK list prices in September 2025. As widely reported at the time, the highest-dose pen's list price rose substantially; typical private monthly costs now range roughly £149–£375 depending on dose and provider. Our dedicated page on the Eli Lilly UK price increase explains what happened and what it means for people starting treatment or already mid-course.

At nume, consultations are reviewed the same day by a named GPhC-registered Independent Prescriber, a real clinician reads your answers, not automated software. If approved, treatment is dispatched the same day for free next-working-day delivery via DPD. You can read more about tirzepatide and how it works to understand what you'd be starting before you commit to anything. If you are a competitive athlete or work in a regulated sport, our page on whether tirzepatide is banned by WADA covers the anti-doping position in detail. And if you want to confirm you're dealing with a properly registered pharmacy, the GPhC register entry for our pharmacy is publicly searchable at GPhC registration 9012878.

Comparing free NHS access with private treatment: things people don't always factor in

It is tempting to frame this as a straightforward cost comparison, free NHS versus paid private. The full picture is more nuanced. NHS access, where it exists, comes with waiting times that vary enormously by area. Some patients have waited six months or more simply to be assessed by a specialist service. Private treatment, by contrast, can begin within a day of a consultation being approved.

There is also the question of supply continuity. During periods of high demand, some NHS prescriptions for GLP-1 medicines have faced fulfilment delays. Private providers sourcing through the licensed UK supply chain (including authorised Eli Lilly relationships) have generally maintained availability, though no provider can guarantee stock at every dose.

For a fuller sense of what accessing tirzepatide privately involves, the page on how to get Mounjaro in the UK walks through the full process. If you're still weighing whether tirzepatide or semaglutide is the right fit, our treatment overview covers both medicines side by side. And if you are ready to find out whether you're clinically suitable now, you can check your eligibility through a free consultation with our prescribers.